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The goal was to test the effects of various combinations of pulse widths (PW) and duty cycles (DC) on
high-intensity focused ultrasound (HIFU)-induced sonothrombolysis efficacy using an in vitro flow model. An
ExAblate™ 4000 HIFU headsystem (InSightec, Inc., Israel) was used. Artificial blood clots were placed into test tubes
inside a human calvarium and exposed to pulsatile flow. Four different duty cycles were tested against four
different pulse widths. For all study groups, an increase in thrombolysis efficacy could be seen in association with
increasing DC and/or PW (p < 0.0001). Using transcranial HIFU, significant thrombolysis can be achieved within
seconds and without the use of lytic drugs in vitro. Longer duty cycles in combination with longer pulse widths
seem to have the highest potential to optimize clot lysis efficacy.
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Reversible disaggregation of fibrin fibers, improved dis-
tribution of plasminogen, tissue plasminogen activator
(tPA) within a blood clot, and cavitational mechanisms
have been described to explain why ultrasound enhances
clot lysis [1-5]. Early clinical studies on transcranial
sonothrombolysis in stroke patients using diagnostic
ultrasound devices were promising. The most relevant
work, so far, was published in 2004 by Alexandrov et al.
[6]. Other studies showed comparable results [7-12],
suggesting that the use of transcranial diagnostic ultra-
sound in combination with tPA shortens the time to re-
canalize vessels significantly. Despite the excitement for
this new treatment approach, it is limited to a minority
of patients since less than 3% of all stroke victims cur-
rently receive tPA. The successful use of HIFU for
sonothrombolysis outside the cranium and without the
additional use of lytic agents, such as tPA, has been de-
scribed earlier [13]. Very recent data showing the feasi-
bility of HIFU for transcranial sonothrombolysis in the* Correspondence: thoelscher@ucsd.edu
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reproduction in any medium, provided the orabsence of tPA [14] demonstrate its future potential as a
noninvasive, drug-independent treatment option for
stroke. However, the data describing the transcranial ap-
plication for potential use in stroke patients are sparse.
Regarding the various ultrasound operating parameters,
such as transmit frequency, acoustic output power, duty
cycle, and pulse width, it is unclear which combination
of these parameters might be preferable to gain effica-
cious sonothrombolysis in a safe manner, trying to avoid
uncontrolled thermal as well as cavitational effects
which are most feared in this regard. Hence, thorough
research has to be done to define the most efficacious
combinations of ultrasound operating parameters to be
applied in such a fashion that thermal as well as cavita-
tion effects can be either avoided or, at least, controlled.
To date, the knowledge about sonothrombolysis param-
eter optimization is very limited. One of the most rele-
vant works in this regard was published by Schafer et al.
[15]. They tested the effect of operating parameters on
the thrombolytic potency of ultrasound and found that
thrombolytic efficiency of ultrasound depends directly
on duration, intensity, duty cycle, and pulse length, and
inversely on frequency. It is important to mention, how-
ever, that the knowledge gained by Schafer et al. is based
on transmit frequencies between 2.0 and 4.5 MHz. Theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hölscher et al. Journal of Therapeutic Ultrasound 2013, 1:18 Page 2 of 5
http://www.jtultrasound.com/content/1/1/18transmit frequency of the device used for the present study is
220 kHz. Therefore, it is questionable whether the results can
be translated to low-frequency ultrasound systems. The goal
of this study was to investigate the impact of varying duty cy-
cles and pulse width on HIFU-induced thrombolysis efficacy,
in the absence of tPA, in a transcranial in vitro flow model.
Methods
Ultrasound system and operating parameters
The ExAblate™ 4000 (InSightec Inc., Tirat Carmel, Israel)
HIFU headsystem has been developed for brain applica-
tions. A key component of this system is a hemispheric
phased array transducer with 1,000 single piezo elements
that can be operated independently. Due to its geometry, a
sharp focus can be generated, located in the center of the
transducer (Figure 1). The transmit frequency of the sys-
tem is 220 kHz.
To test the impact of various duty cycles and pulse
widths on thrombolysis, the decision was made to retain
an insonation duration of 30 s and an acoustic output
power of 235 W for all studies. The parameters above were
chosen due to own data in [14], which show that trans-
cranial thrombolysis can be achieved using these parame-
ters. In the present study, four different duty cycles were
tested in combination with four different pulse widths, as
displayed in Table 1.Figure 1 Top view inside the hemispheric transducer of the ExAblate
ultrasound-transmitting elements (total N = 1,000). All elements transmit to
beam of 4.0-mm diameter in lateral and 6.0 mm in elevational orientation.
given in XY (upper left) and Z (upper right) orientations.Clot preparation
Venous whole blood was drawn from healthy, un-
medicated donors and transferred into citrate tubes. The
donors were enrolled after signing a written informed
consent according to the local Institutional Review
Board approval (Internal Review Board of the University
of California, San Diego). For each clot, 0.5 ml citrate
blood was mixed with 40 μl CaCl2 (210 mmol/l) and
transferred into a borosilicate glass tube, which had a
silk thread inside. The clots were incubated for 3 h in a
37°C water bath. The thrombus was organized around
the silk thread so that it will be kept in place inside the
test tube during insonation. The thrombi had an average
weight of 0.2519 g ± 7%. The average length of each
thrombus was about 2.5 cm.
Experimental setup
A degassed, cadaveric skull specimen was mounted on
an acrylic frame and placed upside down into the de-
gassed water-filled cavity of the hemispheric transducer.
The thrombus inside the test tube was placed at the nat-
ural focus of the transducer, which is located at the geo-
metrical center in X/Y and 15 cm from the bottom in
the Z orientation of the hemispheric array (Figure 2).
For all experiments, the clots were exposed to circu-
lating, pulsatile flow (10 ml/min). Phosphate buffered™ 4000 HIFU headsystem. Each black tile contains nine single
wards the center of the transducer (green star), creating a sharp focus
Parametric images of the focus, based on acoustic measurements, are
Table 1 Combinations of DC, PW, and the total N per
study group
DC (%) PW
0.1 ms 1 ms 10 ms 100 ms
5 N = 40 N = 40 N = 40 N = 40
10 N = 40 N = 44 N = 40 N = 40
20 N = 41 N = 40 N = 41 N = 43
50 N = 43 N = 40 N = 42 N = 44
DC, duty cycles; PW, pulse width.




ISPTA PNEG PPOS N per
group(W/cm2) (MPa) (MPa)
1 13.7 2.8 3.1 40
2 13.7 2.8 3.1 40
3 13.7 2.8 3.1 43
4 13.7 2.8 3.1 43
5 27.4 2.8 3.1 43
6 27.4 2.8 3.1 43
7 27.4 2.8 3.1 43
8 27.4 2.8 3.1 43
9 54.7 2.8 3.1 43
10 54.7 2.8 3.1 43
11 54.7 2.8 3.1 43
12 54.7 2.8 3.1 43
13 136.8 2.8 3.1 43
14 136.8 2.8 3.1 43
15 136.8 2.8 3.1 43
16 136.8 2.8 3.1 44
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temperature inside the hemispheric transducer as well as
inside the test tube was kept at 24°C.
Acoustic field mapping
For each of the 16 different duty cycle (DC)/pulse width
(PW) combinations, the acoustic parameters spatial peak
temporal average intensity (ISPTA), peak negative pressure
(PNEG), and peak positive pressure (PPOS) were measured
using a HIFU hydrophone (Model Y120, Sonic Concepts,
Seattle, WA), calibrated for the frequency of 220 kHz. The
acoustic measurements are presented in Table 2.
Statistical analysis
Percent weight loss within each of the 16 DC/PW com-
binations was compared using a Wilcoxon signed-rank
test. A Kruskal-Wallis test was used to examine the dif-
ferences in clot weight loss among the four PW settings
within each DC group. If the overall difference was sta-
tistically significant, pair-wise comparisons were perfor-
med using a Wilcoxon rank-sum test with the p values
adjusted using a Bonferroni-Holm correction for mul-
tiple comparisons.Figure 2 The hemispheric transducer with the calvarium
(upside down) and thrombus inside the test tube. The tip of the
hydrophone is located 2.0 mm above the natural focus position
(x/y/z is 0/0/150 mm). The thrombus is centered below the
hydrophone tip.Results
Overall, a total of N = 658 experiments were performed.
The results are given in Table 3. For each study group,
the values for average percent weight loss, standard devi-
ation, and percent weight loss per kilo Joule are given.
Three main observations could be made: (1) For all
study groups, the percent weight loss was statistically
significant (p < 0.001). (2) With increasing DCs as well
as increasing PWs, the percent weight loss increased as
well. (3) At a DC of 50%, the change of PW did not lead
to a significant change in weight loss.
A visual presentation of the percent weight loss for
each group, displayed as boxplots, is given in Figure 3.
Discussion
Disregarding the acoustic output power or insonation
duration, it could be demonstrated in vitro that sono-
thrombolysis efficacy using transcranial high-intensity
focused ultrasound is dependent on the combination of
duty cycle and pulse width. Looking at clot weight loss
over time, increased duty cycles in combination with
increased pulse widths seem to be preferable.
The observation of higher clot weight loss with in-
creased duty cycles and pulse widths might be rather ob-
vious at first sight. As shown in Table 2, the ISPTA
increases with higher duty cycles, whereas the ISPTA for
a 5% duty cycle is 13.7 W/cm2; in combination with any
given pulse width, it increases to tenfold using a duty
cycle of 50% (136.8 W/cm2). Accordingly, the energy de-
position at the clot site increases from 100 to 1,000 J.
Table 3 % WT loss mean, Std dev, and pulse ‘off time’ are
given for all 16 parameter combinations
DC (%) PW
0.1 ms 1 ms 10 ms 100 ms
5 GP 1 GP 2 GP 3 GP 4
N 40 40 40 40
% Wt loss (mean) 10.28 17.55 23.62 27.15
Std dev 11.95 7.08 11.97 20.75
Off time (ms) 1.9 19 190 1900
10 GP 5 GP 6 GP 7 GP 8
N 40 44 40 40
% Wt loss (mean) 17.12 24.32 29.08 42.92
Std dev 9.1 15.88 17.33 24.67
Off time (ms) 0.9 9 90 900
20 GP 9 GP 10 GP 11 GP 12
N 41 40 41 43
% Wt loss (mean) 30.02 37.7 39.9 59.6
Std dev 20.12 21.83 21.5 19.16
Off time (ms) 0.4 4 40 400
50 GP 13 GP 14 GP 15 GP 16
N 43 40 42 44
% Wt loss (mean) 48.67 53.58 51.43 59.23
Std dev 23.7 20.85 21.85 17.1
Off time (ms) 0.2 2 20 200
The italicized entries represent the 16 different study groups, i.e., GP14 is
study group #14.% WT loss, percent weight loss; Std dev, standard deviation.
Figure 3 Histogram showing the percent clot weight loss for all 16 st
bars), and 50% DC (blue bars).
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the work published by Schafer et al. [15]. Using a
nonfocused, diagnostic ultrasound transducer in an
in vitro sonothrombolysis setup, three different duty cy-
cles were tested in combination with increasing pulse
widths between 100 and 400 μs. With regard to the par-
ameter duty cycle, the highest amount of thrombolysis
efficacy was seen using a 100% duty cycle, i.e., continu-
ous wave mode. The smallest amount of clot lysis was
seen using a 20% duty cycle. With regard to the operat-
ing parameter pulse width, the investigators described
only a modest effect. Given a constant duty cycle, in-
creased pulse widths caused higher clot weight loss as
well, however, to less extent. This could be confirmed in
the present study. A possible reason why an increase in
clot weight loss can be observed with greater pulse
widths, although duty cycle, intensity, and total energy
remain constant, might be that the total number of
pulses per insonation duration decreases. That implies
that each pulse simply contains more energy and, there-
fore, presumably improves clot/fibrin disaggregation.
Noteworthy is the observation that increased clot weight
loss was rather distinct using short duty cycles in combin-
ation with increased pulse widths, whereas the change of
pulse width using longer duty cycles, such as 50% in the
present study, diminished.
In the present study, only the parameters duty cycle
and pulse length were changed, whereas the parameters
acoustic output power and insonation duration remained
unchanged. Accordingly, the acoustic intensities varied
between the study groups with the lowest ISPTA seen in
the 5% DC and the highest ISPTA values in the 50% duty
cycle groups, as shown in Table 2. Rosenschein et al. [13]
followed a similar approach to investigate the potentialudy groups. 5% DC (red bars), 10% DC (green bars), 20% DC (yellow
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They tested five pulse lengths (50, 100, 200, 300, and
400 μs) against various duty cycles (10%, 5%, 4%, 3.3%,
and 2.5%), but—different from the present study—they
adapted the acoustic output power to keep the ISPTA at the
focal spot constant at 40 W/cm2 throughout all study
groups. The total insonation duration was 4 min and
remained unchanged as well. Differing from the present
study, they found an optimized clot lysis efficiency using a
short duty cycle of 4% and a pulse length of 200 μs.
The major limitation of the present study is the miss-
ing translation into an appropriate in vivo model. A
sonothrombolysis rabbit model has been established re-
cently to investigate whether the rather promising
in vitro results can be confirmed in a living system. Of
greatest importance will be to investigate whether this
application might cause vascular damage or unwanted
blood–brain barrier opening, and if the latter should be
the case, what could be done to significantly improve
the safety profile. In addition, temperature assessments
are missing in the present work. Although there is a
common belief that the underlying mechanism of clot/
fibrin disaggregation is of mechanical nature, thermal
effects cannot be excluded until appropriate measure-
ments or appropriate calculations are available, more so
since temperature elevation during sonothrombolysis
would be a serious safety issue. Regarding safety, poten-
tial clot fragmentation is of concern as well.Conclusion
Using transcranial HIFU, significant thrombolysis can be
achieved within seconds and without the use of lytic drugs.
Aiming ultrasound operating parameter optimization, the
present data show that the combination of long duty cycles
and long pulse widths seems preferable. A duty cycle of
50% seems to represent an upper limit above which a
change of the pulse width does not affect the thrombolysis
efficacy. The current findings might be taken into consider-
ation for future translational research on HIFU-induced
thrombolysis. The development of a noninvasive, transcra-
nial ultrasound technology which provides the possibility
to treat stroke victims who are not eligible for tPA would
be a significant achievement in today's stroke care.
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